Endo International plc (ENDP)
Chart Events
Performance Outlook
| Previous Close | 6.05 |
| Open | 6.11 |
| Bid | 6.00 x 3100 |
| Ask | 6.78 x 3000 |
| Day's Range | 5.95 - 6.28 |
| 52 Week Range | 2.71 - 10.89 |
| Volume | 3,134,833 |
| Avg. Volume | 3,704,730 |
| Market Cap | 1.443B |
| Beta (5Y Monthly) | 1.56 |
| PE Ratio (TTM) | 7.94 |
| EPS (TTM) | 0.79 |
| Earnings Date | May 06, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.70 |
Fair Value
Related Research
- PR Newswire
Endo to Announce First Quarter 2021 Financial Results
Endo International plc (NASDAQ: ENDP) will announce its first-quarter 2021 financial results on May 6, 2021 and members of its senior management team will host a conference call and webcast on May 7, 2021 at 7:30am ET before the U.S. financial markets open.
- CNW Group
Endo Announces Publication of Phase 3 Qwo® (collagenase clostridium histolyticum-aaes) Data in Peer-Reviewed Dermatologic Surgery
Endo International plc (NASDAQ: ENDP) today announced that Phase 3 data evaluating Qwo® (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women was published in Dermatologic Surgery, the official journal of the American Society for Dermatologic Surgery. In addition to Phase 3 studies, the publication also includes a supplemental video that demonstrates the injection techniques for QWO.
- CNW Group
ADVANZ PHARMA and Endo Announce Partnership for Paladin Labs to Commercialize Xydalba® (dalbavancin hydrochloride) in Canada
Endo International plc (NASDAQ: ENDP) and ADVANZ PHARMA Corp. Limited, a specialty pharmaceutical company with a strategic focus on complex medicines, are pleased to announce today that Endo International plc's subsidiary Endo Ventures Limited has entered into a definitive agreement with Correvio International Sà rl entity, a subsidiary of ADVANZ PHARMA, to commercialize and distribute on an exclusive basis Xydalba® (dalbavancin hydrochloride) in Canada.
